Pulmokine is a privately held biopharmaceutical company. Our focus is on pulmonary disease and kinase inhibitor technology, hence our name Pulmokine.
The mission of Pulmokine is to develop new therapies for hard-to-treat lung conditions like pulmonary arterial hypertension (PAH) and related disorders. These include pulmonary arterial fibrosis/interstitial lung disease, sarcoidosis and lung cancer.
Pulmokine has an exclusive license from Gilead to develop a portfolio of PDGFR inhibitors for PAH. Funding sources include equity investment and NIH grants. We pursue in-licensing and partnership opportunities related to pulmonary and cardiovascular diseases.
In addition, Pulmokine is developing a novel class of kinase inhibitors through in silico modeling and in vitro screening.